Moody’s upgrades Agnico Eagle’s rating to A3 on debt reduction
Investing.com - Oppenheimer has resumed coverage of Centessa Pharmaceuticals (NASDAQ:CNTA) with an Outperform rating and a $40 price target. According to InvestingPro data, analysts maintain a Strong Buy consensus with price targets ranging from $27 to $38, suggesting significant upside potential from the current price of $16.56.
The research firm previously had the stock listed as Not Rated before issuing the new rating on Friday. Oppenheimer cited strong conviction in Centessa’s lead asset ORX750, which it believes has best-in-class potential among orexin-2 receptor agonists. The company, with a market capitalization of $2.42 billion, maintains strong liquidity with a current ratio of 10.12, as revealed by InvestingPro analysis.
Oppenheimer expects near-term Phase 2a CRYSTAL-1 data in idiopathic hypersomnia and narcolepsy type-1 and type-2 later this year, likely in the fourth quarter of 2025 based on clinical trial information. While the company reported revenue growth of 119% in the last twelve months, InvestingPro indicates it operates with moderate debt levels and maintains healthy liquid assets exceeding short-term obligations.
The firm highlighted upcoming presentations at World Sleep on September 8, 2025, for other OX2R agonists that should inform the competitive landscape for ORX750. Oppenheimer believes ORX750 has substantial market opportunity due to current polypharmacy dynamics, key opinion leader optimism supporting real-world uptake in early treatment lines, and fast-follower positioning.
Oppenheimer forecasts $2.5 billion in peak risk-adjusted sales for the drug by 2040, drawing on its existing coverage of the narcolepsy sector including companies like Axsome Therapeutics and Harmony Biosciences.
In other recent news, Centessa Pharmaceuticals has been the focus of several significant developments. Truist Securities has reiterated its Buy rating for Centessa Pharmaceuticals, maintaining a price target of $30.00. This comes ahead of the anticipated release of Phase 2a data for their ORX750 treatment, aimed at addressing narcolepsy. The firm had previously initiated coverage with a Buy rating, highlighting the potential of ORX750, which also targets idiopathic hypersomnia. In addition to these analyst activities, Centessa Pharmaceuticals announced an executive change with Raphael Deferiere appointed as the new Chief Accounting Officer, effective May 27, 2025. Deferiere, who brings extensive experience from his previous role as an Assurance Partner at Ernst & Young, will also serve as the principal accounting officer. These developments mark a period of strategic moves for Centessa Pharmaceuticals, as they await critical data on their ORX750 treatment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.